Between 2024 and 2028, the mortality rate for bladder malignant neoplasms in Canada is forecasted to decrease from 8.9 to 8.4 male deaths per hundred thousand men. This reflects a consistent decline in mortality rates, with a year-on-year decrease ranging from approximately 1.12% to 2.30% annually. The average compound annual growth rate (CAGR) over the five-year period is declining, suggesting an overall positive trend in healthcare outcomes.
Future trends to watch for include the integration of advanced diagnostic measures, targeted treatments, and public health strategies aimed at early detection and prevention. Monitoring the impact of healthcare accessibility and quality on mortality rates is also crucial.
